background   The effects of the non-stimulant drug, atomoxetine, on children with attention-deficit hyperactivity disorder (adhd) are currently under study. So far, it is only American research that has reported a reduction in adhd-symptoms following treatment with atomoxetine.
aim  To evaluate the safety and effectiveness of atomoxetine when used to treat Belgian schoolchildren.
method  The effects of atomoxetine in the treatment of 36 children (aged from 6 to 13) were investigated via a prospective open-label study. The efficacy was assessed by means of parent-ratings of adhd-symptoms at each visit and by means of a questionnaire completed by the patients principal teacher on 3 occasions. Side-effects and cardiovascular parameters were monitored and blood tests were taken.
results   Treatment with atomoxetine (mean final dose 1.55 mg/kg/day) was well tolerated. Atomoxetine significantly reduced the core symptoms of adhd. Of the 36 children, 21 (58%) satisfied the response-criteria (>25% decrease on adhd-Rating Scale-iv-Parent Version - Investigator Administered and Scored, and a final Clinical Global Impression Severity Scale - adhd score ≤2). Of the 21 children who completed the 10-week course, 20 (95%) satisfied the response-criteria. conclusions The Belgian findings correspond to the positive results reported in the controlled American studies and should encourage centres in many other countries to conduct further trials with atomoxetine.